AGR2 and neoplasm: In vivo, xenografts with AGR2-KD performed elevated tumor suppression compared to PC3-NC in response to crizotinib (Fig. 6d, e and Supplementary Fig. 9d, e) without showing signs of severe toxicity (Supplementary Fig. 9f), suggesting that AGR2 loss exacerbated crizotinib-induced inhibition and may serve as a biomarker for crizotinib responses in vivo.